Literature DB >> 8391038

Differences in the hepatitis C virus genotypes in different countries.

N Takada1, S Takase, A Takada, T Date.   

Abstract

We recently classified the hepatitis C virus (HCV) into 4 types (HCV-PT, -K1, -K2a and -K2b) according to differences in nucleotide sequences. It was found that HCV-PT, the prototype reported from the U.S.A., was rare in Japan, suggesting that distribution of HCV genotypes may be different in various countries. The prevalence of HCV genotypes was therefore compared in different countries. Genotyping of HCV was performed by slot-blot hybridization analysis using cDNA probes specific to each type of HCV or by restriction fragment length polymorphism analysis. In 121 Japanese non-cancer patients, the prevalence of HCV genotypes was 77.7% for HCV-K1, 16.5% for HCV-K2a and 5.0% for HCV-K2b. HCV-PT was detected in only 1 patient (0.8%). The prevalence in 43 Japanese hepatocellular carcinoma (HCC) patients was 74.4% for HCV-K1, 18.6% for HCV-K2a and 4.7% for HCV-K2b. HCV-PT was found in only 1 sample. In 19 European non-cancer patients, HCV-PT was found in 42.1% and HCV-K1 was found in 52.6%. HCV-K2 was not found. All 7 samples from European HCC patients were HCV-K1, indicating a significantly higher prevalence than in non-cancer patients. In 13 Brazilian non-cancer patients, the distribution pattern was similar to that of the Europeans. In 10 samples from the U.S.A., HCV-PT was found in 70% and HCV-K2 was found in 1 sample. In 18 Chinese non-cancer patients, HCV-K1 was found in 44.4%, HCV-K2a in 50.0% and HCV-K2b in 5.6% HCV-PT was not found. Two samples from Chinese HCC patients were HCV-K1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8391038     DOI: 10.1016/s0168-8278(05)80205-3

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  44 in total

1.  Hepatitis C virus serotypes and sources of infection in patients with HCV-related chronic liver disease from one geographical area in southeast Italy.

Authors:  P Dentico; N Curatolo; R Sacco; M De Luca; A Volpe; C Ranieri; C Genchi; L Petracca; R Buongiorno
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

2.  A computer model of the spread of hepatitis C virus among injecting drug users.

Authors:  D Mather; N Crofts
Journal:  Eur J Epidemiol       Date:  1999-01       Impact factor: 8.082

Review 3.  Hepatitis C virus and lymphoma.

Authors:  D S Viswanatha; A Dogan
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

4.  Subtyping of hepatitis C virus isolates by a line probe assay using hybridization.

Authors:  A Andonov; R K Chaudhary
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

5.  Molecular characterization and clinical epidemiology of HCV in District Dir (Lower), Pakistan.

Authors:  Sami Ullah; Muhammad Akram Khan; Shafiq Ur Rahman; Imran Khan; Fazal Akbar; Anshu Babbar
Journal:  Virusdisease       Date:  2018-05-17

6.  Genotyping of hepatitis C virus in South Africa.

Authors:  H E Smuts; J Kannemeyer
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

7.  Interferon treatment of chronic hepatitis C in patients with hemophilia or von Willebrand's disease in Japan.

Authors:  M Yoshikawa; H Fukui; H Kojima; H Yoshiji; T Sakamoto; H Imazu; T Nakanani; Y Matsumura; S Kuriyama; J Yamao
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

8.  Molecular epidemiology of Hepatitis C virus genotypes in Khyber Pakhtoonkhaw of Pakistan.

Authors:  Amjad Ali; Habib Ahmed; Muhammad Idrees
Journal:  Virol J       Date:  2010-08-26       Impact factor: 4.099

9.  Diversity of Hepatitis C virus in Southern India Based on 5'UTR Sequence.

Authors:  R Amjesh; Achuthsankar S Nair; V S Sugunan
Journal:  Indian J Virol       Date:  2012-09-25

10.  Efficacy of combination therapy with interferon and azidothymidine in chronic type C hepatitis: a pilot study.

Authors:  M Tsutsumi; A Takada; M Sawada
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.